On treatment prediction of post-treatment sustained response to Peginterferon alfa-2a for HBeAg-negative Chronic Hepatitis B (CHB) patients using HBsAg and HBV DNA levels at weeks 12 and 24: PERSEAS cohort final results

被引：0

作者：

Goulis, Ioannis ^{[1
]}

Karatapanis, Stylianos ^{[2
]}

Akriviadis, Evangelos A. ^{[1
]}

Deutsch, Melanie ^{[3
]}

Dalekos, George N. ^{[4
,5
]}

Raptopoulou-Gigi, Maria ^{[3
]}

Mimidis, Konstantinos ^{[6
]}

Germanidis, Georgios ^{[7
]}

Triantos, Christos K. ^{[8
]}

Drakoulis, Christos ^{[9
]}

Chounta, Athina ^{[10
]}

Vafiadis, Irene ^{[11
]}

Hatzis, Grigorios ^{[12
]}

Gagalis, Asterios ^{[13
]}

Vlachogiannakos, Jiannis ^{[11
]}

Zintzaras, Elias ^{[14
,15
]}

Koulouris, Sokratis ^{[16
]}

Bakalos, George ^{[14
,16
]}

Papatheodoridis, George V. ^{[3
]}

机构：

[1] Hippokrateion Hosp, Dept Internal Med 4, Thessaloniki, Greece

[2] Rhodes Hosp, Dept Internal Med 1, Rhodes, Greece

[3] Hippokrateion Hosp, Dept Internal Med 2, Athens, Greece

[4] Univ Thessaly, Sch Med, Dept Med, Larisa, Greece

[5] Univ Thessaly, Res Lab Internal Med, Larisa, Greece

[6] Democritus Univ Thrace, Sch Med, Dept Internal Med 1, Alexandroupolis, Greece

[7] AHEPA Hosp, Dept Gastroenterol, Internal Med Clin 1, Thessaloniki, Greece

[8] Univ Patras, Sch Med, Dept Gastroenterol, Patras, Greece

[9] Nikaia Hosp, Dept Internal Med 2, Athens, Greece

[10] Univ Hosp ATTIKON, Dept Internal Med, Athens, Greece

[11] Laiko Univ, Gen Hosp, Dept Internal Med Propaedeut, Athens, Greece

[12] Laikon Gen Hosp, Physiopathol Dept, Athens, Greece

[13] Papageorgiou Gen Hosp, Dept Gastroenterol, Thessaloniki, Greece

[14] Univ Thessaly, Sch Med, Dept Biomath, Larisa, Greece

[15] Tufts Univ, Sch Med, Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA 02111 USA

[16] Roche Hellas, Med Affairs, Athens, Greece

来源：

HEPATOLOGY | 2013年 / 58卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1015

引用

页码：697A / 698A

页数：2

共 50 条

[1] Early On-Treatment Prediction of Response to Peginterferon Alfa-2a for HBeAg-Negative Chronic Hepatitis B Using HBsAg and HBV DNA Levels
Rijckborst, Vincent
Hansen, Bettina E.
Cakaloglu, Yilmaz
Ferenci, Peter
Tabak, Fehmi
Akdogan, Meral
Simon, Krzysztof
Akarca, Ulus S.
Flisiak, Robert
Verhey, Elke
Van Vuuren, Anneke J.
Boucher, Charles A. B.
ter Borg, Martijn J.
Janssen, Harry L. A.
HEPATOLOGY, 2010, 52 (02) : 454 - 461
[2] HBSAG LEVELS DURING THE FIRST 24 WEEKS OF PEGINTERFERON ALFA-2A [40KD] (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B: THE PERSEAS COHORT
Goulis, I.
Akriviadis, E.
Karatapanis, S.
Deutsch, M.
Dalekos, G.
Raptopoulou-Gigi, M.
Drakoulis, C.
Bakalos, G.
Papatheodoridis, G.
JOURNAL OF HEPATOLOGY, 2011, 54 : S286 - S287
[3] EARLY PREDICTION OF SUSTAINED RESPONSE TO PEGINTERFERON ALFA-2A IN HBEAG-NEGATIVE PATIENTS: THE ROLE OF ON-TREATMENT HBSAG AND HBV DNA LEVELS
Rijckborst, V.
Hansenu, B. E.
Cakaloglu, Y.
Ferenci, P.
Tabak, F.
Akdogan, M.
Simon, K.
Akarca, U. S.
Flisiak, R.
Verhey, E.
van Vuuren, A. J.
Boucher, C. A. B.
ter Borg, M. J.
Janssen, H. L. A.
JOURNAL OF HEPATOLOGY, 2010, 52 : S4 - S5
[4] On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients
Goulis, Ioannis
Karatapanis, Stylianos
Akriviadis, Evangelos
Deutsch, Melanie
Dalekos, George N.
Raptopoulou-Gigi, Maria
Mimidis, Konstantinos
Germanidis, George
Drakoulis, Christos
Triantos, Christos
Zintzaras, Elias
Bakalos, Georgios
Papatheodoridis, George
LIVER INTERNATIONAL, 2015, 35 (05) : 1540 - 1548
[5] HBSAG LEVELS DECLINE DURING PEGINTERFERON ALFA-2A [40KD] (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B FAVORS 6 MONTHS POST-TREATMENT RESPONSE: PERSEAS COHORT INTERIM ANALYSIS
Goulis, I.
Akriviadis, E.
Karatapanis, S.
Deutsch, M.
Dalekos, G.
Raptopoulou-Gigi, M.
Mimidis, K.
Germanidis, G.
Triantos, C.
Drakoulis, C.
Chounta, A.
Tsoplou, F.
Zintzaras, E.
Bakalos, G.
Papatheodoridis, G.
JOURNAL OF HEPATOLOGY, 2012, 56 : S201 - S202
[6] IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B HBSAG SERUM LEVELS EARLY DURING TREATMENT WITH PEGINTERFERON ALFA-2A PREDICT HBSAG CLEARANCE 4 YEARS POST-TREATMENT
Marcellin, Patrick
Brunetto, Maurizia
Bonino, Ferruccio
Hadziyannis, Stephanos J.
Kapprell, Hans-Peter
McCloud, Philip I.
Batrla, Richard
HEPATOLOGY, 2008, 48 (04) : 718A - 719A
[7] A NOVEL COMBINATION REGIMEN OF PEGINTERFERON ALFA-2A AND ENTECAVIR RESULTS IN SUSTAINED POST-TREATMENT HBSAG CLEARANCE IN HBEAG-POSITIVE CHRONIC HEPATITIS B (CHB)
Sheng, Jifang
Bai, Xuefan
Wu, Shuhuan
Chen, Jianjie
Sheng, Jifang
Xie, Yao
Chen, Chengwei
Jiang, Michael
Xie, Ding
HEPATOLOGY, 2011, 54 : 1017A - 1017A
[8] A GENOTYPE-SPECIFIC BASELINE SCORE TO PREDICT RESPONSE AT 48 WEEKS POST-TREATMENT TO PEGINTERFERON ALFA-2A IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B
Lampertico, P.
Messinger, D.
Cornberg, M.
Brunetto, M.
Petersen, J.
Kennedy, P.
Asselah, T.
Rothe, V.
Caputo, A.
Bakalos, G.
Pavlovic, V.
Papatheodoridis, G. V.
JOURNAL OF HEPATOLOGY, 2016, 64 : S599 - S600
[9] HBSAG LEVELS DECLINE > 10% DURING 48 WEEKS OF PEGINTERFERON ALFA-2A [40KD] (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITS B (CHB) FAVORS END OF TREATMENT RESPONSE: PRELIMINARY ANALYSIS OF THE PERSEAS COHORT
Goulis, Loannis
Akriviadis, Evangelos
Karatapanis, Stylianos
Deutsch, Melanie
Dalekos, George N.
Raptopoulou-Gigi, Maria P.
Drakoulis, Christos
Mimidis, Konstantinos
Germanidis, Georgios
Nikolopoulou, Vasiliki
Chounta, Athina
Bakalos, George
Papatheodoridis, George V.
HEPATOLOGY, 2011, 54 : 1019A - 1020A
[10] RESPONSE TO PEGINTERFERON ALFA-2A IN HBEAG-NEGATIVE CHB: BASELINE AND ON-TREATMENT KINETICS OF HBSAG SERUM LEVELS VARY ACCORDING TO HBV GENOTYPE
Brunetto, Maurizia R.
Marcellin, Patrick
Cherubini, Beatrice
Yurdaydin, Cihan
Farci, Patrizia
Hadziyannis, Stephanos J.
Rothe, Vivien
Regep, Loredana
Kapprell, Hans-Peter
Bonino, Ferruccio
HEPATOLOGY, 2011, 54 : 1059A - 1059A

← 1 2 3 4 5 →